This Is MS Multiple Sclerosis Knowledge & Support Community

I suppose this is to be expected for a company without a retail product undergoing an expensive R & D process with its lead candidate.

Opexa Therapeutics 4Q Loss Widens
Opexa Therapeutics' 4th-Quarter Loss Widens on Higher Research and Development Costs
March 18, 2008: 09:22 AM EST

NEW YORK (Associated Press) - Biotechnology company Opexa Therapeutics Inc. said Tuesday its 2007 loss widened on higher research and development expenses.

The company lost $14.7 million, or $2.19 per share, compared with a loss of $12.6 million or $2.35 per share. The company had no revenue in 2007 or 2006. Opexa had about 1.3 million additional shares in 2007.

Opexa did not report fourth-quarter results.

Research and development expenses rose 70 percent to about $13.1 million, primarily due to midstage studies of the company's experimental multiple sclerosis treatment Tovaxin.

More details can be found at this page.

NHE

It's about time for the Cavalry to come riding over the horizon.
Lars

I wonder if they could get funding from the "fast-forward" effort being done by the nmss.

Lars wrote:It's about time for the Cavalry to come riding over the horizon.
Lars

Tim,

Do you have any comments on the business side of Opexa that will help to calm our fears about whether or not Opexa is going to have enough money to complete the IIb, extension and phase III trials?

Mike

see: <shortened url>

Sorry about the link, probably won't work. Try going to http://www.pharmafrontierscorp.com/ and then look at the upper left corner under news. I think Opexa is going to make a pitch to Cambria Capital Investors.

would it help if we send Cambria some cupcakes or brownies?

.

Hi Lyon,
Tim provided some info on the "going concern" statement last November in this thread. Opexa's recent round of fund raising should carry them through the end of this year. Hopefully, the results of the current phase IIB study will get more investors on line so that they can successfully complete a phase III.

NHE

.

Seems to me that nothing matters except the long anticipated IIB study data. When that information is released the well will either dry up or there will be a financial flood of epic proportions. OK, maybe somewhere in between. Obviously $'s will be directly related to effectiveness.
Hoping for good results,
Lars

.

Opexa

.

Chris,
Holy S**t. I'm sorry for you and your site mates. I have not heard any stories about anyone being dropped. Maybe its time to keep a really close ear to the ground. Big ??????????'s

PS.
Bob, Can you imagine a scenario where all 5 patient would go from RR to Progressive at the same site at the same time. I can't.
Take Care,
Lars